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A B S T R A C T
Previous studies have shown that prolyl oligopeptidase (PREP) negatively regulates autophagy and increases the
aggregation of alpha-synuclein (αSyn), linking it to the pathophysiology of Parkinson’s disease. Our earlier
results have revealed that the potent small molecular PREP inhibitor KYP-2047 is able to increase autophagy and
decrease dimerization of αSyn but other PREP inhibitors have not been systematically studied for these two
protein-protein interaction mediated biological functions of PREP. In this study, we characterized these effects
for 12 known PREP inhibitors with IC50-values ranging from 0.2 nM to 1010 nM. We used protein-fragment
complementation assay (PCA) to assess αSyn dimerization and Western Blot of microtubule-associated protein
light chain 3B II (LC3B-II) and a GFP-LC3-RFP expressing cell line to study autophagy. In addition, we tested
selected compounds in a cell-free αSyn aggregation assay, native gel electrophoresis, and determined the
compound concentration inside the cell by LC-MS. We found that inhibition of the proteolytic activity of PREP
did not predict decreased αSyn dimerization or increased autophagy, and we also confirmed that this result did
not simply reflect concentration differences of the compounds inside the cell. Thus, PREP ligands regulate the
effect of PREP on autophagy and αSyn aggregation through a conformational stabilization of the enzyme that is
not equivalent to inhibiting its proteolytic activity.
1. Introduction
Prolyl oligopeptidase (PREP) (EC 3.4.21.26) is a serine protease
with an endopeptidase activity, cleaving peptides smaller than 30
amino acids from the carboxyl side of a proline residue [1]. PREP
consists of two domains: An α/β hydrolase fold and a seven-bladed β-
propeller domain which is thought to prevent larger peptides from
entering the active site [2]. PREP is expressed in various tissues in both
periphery and CNS, where the highest concentrations are found in the
liver and testis, and in the brain cortical and nigrostriatal areas [3–5].
Even though some biologically active substrates for PREP, such as
substance P, arginine-vasopressin, and thyrotropin-releasing hormone
have been identified as in vitro PREP substrates, the physiological role
of PREP is still unclear [6]. However, alterations in PREP activity have
been observed in neurological conditions, such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, mania, clinical depression,
dementia, and autism [7]. This has led to the development of small-
molecular PREP inhibitors aiming to block neuropeptide catabolism.
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Although several PREP inhibitors have showed beneficial effects in
preclinical memory models, and S17092, Z-321 and JTP-4819 were also
tested in clinical trials as memory enhancers, their impact on neuro-
peptide levels remained unclear and clinical efficacy was not sufficient
to support further studies [8,9].
Several functions of PREP cannot be directly linked to its proteolytic
activity, for example regulation of inositol-1,4,5-triphosphate signaling
[10], regulation of intracellular protein trafficking and protein secre-
tion [11], modulation of neutrophilic inflammation [12], and neuronal
cell development and differentiation [13]. This has raised interest for
research into direct protein-protein interactions, and lately several in-
teraction partners for PREP such as tubulin [11], glyceraldehyde-3-
phosphate dehydrogenase [14], and growth associated protein 43 [13],
have been identified. PREP has also been shown to be involved in the
alpha-synuclein (αSyn) aggregation process although αSyn is not a
substrate of PREP [15,16]. αSyn inclusions are connected to several
neurodegenerative disorders such as Parkinson´s disease and dementia
with Lewy bodies, and it also co-aggregates with Tau in Alzheimer’s
disease [17–19]. Inhibition of PREP with the small molecule KYP-2047
has been shown to decrease αSyn dimerization and increase autophagy,
which is the main route for cells to degrade aggregated proteins in vivo
and in vitro[16,20,21]. Additionally, we recently reported that PREP
interacts with several proteins in the regulatory complex of protein
phosphatase 2A (PP2A), including the catalytic subunit of PP2A, and
that PREP inhibition or deletion activates PP2A, leading to induction of
beclin-1 dependent autophagy [22]. We showed in an earlier study that
PREP directly interacts with αSyn in vitro and in cells, and this leads to
αSyn dimerization and aggregation [21]. Interestingly, the ability of
PREP to increase αSyn dimerization is independent of its proteolytic
activity as the proteolytically inactive S554A-PREP-mutant also
Table 1
Tested PREP inhibitors and their IC50-values against porcine PREP with references.
Compound Structure mol weight LogPb(Shake flask
method)
IC50 (nM,pig PREP) Reference
SUAM-1221 314.4290 – 2.0 Saito et al 1990 [31] Wallén et al 2002 [32]
KYP-2047 339.4412 1.6 0.2 Jarho et al 2004 [33]
KYP-2087 288.3910 – 147 Kilpeläinen et al 2019 [34]
KYP-2091 410.5580 – 1010 Wallén et al 2002 [32]
KYP-2101 370.5730 3.3 1.2 Wallén et al 2002 [35]
KYP-2108 360.4100 – 0.28 Unpublished data referred to in Wallén 2003
[36]
KYP-2112 517.6600 0.7 0.32 Wallén et al 2003 [37]
KYP-2117 428.5730 2.3 0.26 Wallén et al 2003 [38]
KYP-2153 323.3960 – 0.38 Gynther et al 2004 [39]
KYP-2189 327.4420 – 3 Jarho et al 2007 [40]
ZPP 330.3840 – 0.4 Wilk et al. 1983 [26] Wallén et al 2002 [32]
S17092 384.5830 – 1.5a Barelli et al 1999 [41]
a Ki value against human PREP.
b Determined as described in Jarho et al. [33].
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increases the dimerization of αSyn. This suggested that different PREP
conformations can either induce or inhibit αSyn dimerization. PREP has
at least three different conformations which are seen in native gel
electrophoresis presumably representing an open, a closed, and an
oligomeric form of the enzyme [23]. Moreover, it has been shown that
binding of PREP inhibitor KYP-2047 stabilizes the B and His-loops of
PREP which are flexible structures located near the entry site of the
catalytic cavity [24]. This effect is not visible in the native gel, and
there are reports showing that PREP has several conformations in dy-
namic equilibrium [25]. These findings indicate that certain PREP li-
gands could modify these protein-protein interaction mediated func-
tions via conformational stabilization of the enzyme.
Typical PREP inhibitors are substrate-like peptidic compounds, N-
benzyloxycarbonyl-L-prolyl-L-prolinal (ZPP) being the first discovered
PREP inhibitor [26]. Most of the potent PREP inhibitors are based on
the peptidic N-acyl-L-prolyl-pyrrolidine scaffold or they are close mi-
metics of it [27]. The P1 site is usually a pyrrolidine ring with an
electrophilic group such as nitrile, aldehyde or hydroxyacetyl group in
its 2S-position reacting with the nucleophilic Ser554 at the active site of
PREP [28,29]. The P2 site is usually an α-aminoacyl group and P3 site
is a lipophilic acyl group such as a 4-phenyl-butanoyl group. The widely
used preclinical substrate-like inhibitor KYP-2047 is a slow, tight-
binding inhibitor of proteolytic activity of PREP. Moreover, it has been
shown to effectively enter the brain in mice when administered sys-
tematically [30]. Based on this, our research group have used KYP-2047
as a reference compound in our previous studies on αSyn aggregation
and autophagy [16,20,21]. However, there are no reports where PREP
inhibitors have been widely screened for their ability to decrease αSyn
aggregation or to induce autophagy, and therefore, this study was un-
dertaken to investigate how structurally diverse PREP inhibitors affect
different functions of PREP.
2. Materials and methods
2.1. Chemicals and inhibitors
We selected 12 known structurally diverse PREP inhibitors (pre-
sented in Table 1), received from the old compound library from Uni-
versity of Kuopio (current University of Eastern Finland (UEF)). Other
reagents, including ZPP (SML0205) and S-17092 (SML0181) were
purchased from Sigma-Aldrich unless otherwise stated in the text.
2.2. Determination of autophagy marker LC3B-II levels
Cell culture and lysate preparation. HEK-293 cells were used
throughout the experiment. Cells were obtained from ATCC (Manassas,
VA) and they were authenticated by the Technology Center of Institute
of Molecular Medicine Finland (FIMM, Helsinki, Finland). Cells were
used at the passages 4−15. Cells were cultured in full Dulbecco’s
modified Eagle’s medium (DMEM) with an additional 10% (v/v) FBS
(Invitrogen), 1% (v/v) penicillin-streptomycin solution (Lonza) at 37 °C
and 5% CO2, water-saturated air. 400 000/cells per well were seeded
on 6-well plates, and 24 h post plating cells were treated with tested
compounds at 1 μM concentration for 4 h. After treatment, cells were
lysed with mRIPA buffer (Tris−HCl 50 mM, NaCl (150 mM, 0.25%
sodium deoxycholate, 1% NP-40, pH 7.4) with 1:100 protease inhibitor
cocktail (Product# P8340, Sigma) and HALT phosphate inhibitor
cocktail (Product# 87786, Thermo Fisher Scientific). Lysates were so-
nicated and centrifuged at 13,300 rpm for 15 min at 4 °C. Supernatants
were collected and protein amounts were determined by the BCA
method.
Western Blot (WB). The levels of autophagy markers (autophago-
some marker microtubule-associated protein light chain 3B I–II
(LC3BI–II)) was determined by WB as described earlier in Svarcbahs
et al. [42]. Samples (20 μg protein/sample) were loaded onto a 12%
polyacrylamide-SDS gel and standard transfer and blocking techniques
were used. β-actin served as the loading control. Goat anti-rabbit HRP-
conjugated secondary antibody (dilution 1:2000 in 5% milk; #31460,
RRID:AB_228341, Thermo Fischer Scientific) was used for β-actin (di-
lution 1:2000 in 5% milk; ab8227, RRID:AB_2305186, AbCam) and
LC3BI–II (1:1000 in 5% milk; #L7543, RRID:AB_796155, Sigma). Both
antibodies gave one band corresponding to their correct molecular
weight, and LC3BI-II antibody was tested with positive and negative
controls in our previous study [20]. The images were captured using the
C-Digit imaging system (Licor, Lincoln, USA) and 4–7 independent WB
experiments were performed. Optical density (OD) of the bands were
analyzed with ImageJ (histogram area analysis; version 1.48; National
Institute of Health, Bethesda, MD), and the values were normalized to
the loading control OD values.
2.3. Determination of autophagic flux with GFP-LC3-RFP cell line
HEK-293 cells stably expressing GFP-LC3B-RFP construct described
in Kaizuka et al. [43] were created by using the protocol described in
Svarcbahs et al. [22]. Shortly, HEK-293 cells were seeded at a density of
4 × 105 cells per well on 6-well plates and transfected with pMRX-IP-
GFP-LC3-RFP plasmid (2500 ng/well; #84573, Addgene, Noboru Mi-
zushima Lab; RRID:Addgene_84573) using Lipofectamine 3000
(#L3000015, ThermoFisher Scientific) transfection reagent according
to the manufacturer’s protocol. After 48 h, selection with 3 μg/mL
puromycin cells were seeded on 96-well plates in single cell suspension,
and followed based on their GFP expression. Selected cell colonies ex-
pressing GFP-LC3B-RFP were cultured further and used in experiments.
Procedure for autophagic flux determination was described in
Svarcbahs et al. [22]. GFP-LC3B-RFP expressing HEK-293 cells were
plated on black poly-L-lysine coated 96-well plates at a density of
35,000 cells/well. Tested compounds were used with concentration of
10 μM, rapamycin (0.5 μM; BML-A275, Enzo Life Sciences) was used as
a positive control for autophagic flux induction and bafilomycin 1A (20
nM; SML1661) as an autophagy inhibitor. At 24 h post treatment, cells
were washed twice with warm PBS and GFP signal was read by Victor2
multilabel counter (PerkinElmer; excitation/emission 485 nm/535 nm).
For each experimental condition, 4 replicate wells were used in each
experiment, and at least 3 independent experiments were performed.
Only GFP signal was used in the analysis since RFP signal was not
reliably detectable in well-plate format (see supplementary Table S1
and Fig. S1), and in this construct RFP may also be degraded by lyso-
somes to a certain extent [43]. Representative pictures from GFP-LC3-
RFP expressing cells were taken by Leica DMi8 fluorescence microscope
(Leica Microsystems, Wetzlar, Germany).
2.4. Native gel electrophoresis
For detection of PREP conformations, native gel electrophoresis was
used as described earlier in Savolainen et al. 2015 [21]. Briefly, 10%
separating gel (40% acrylamide/bis 2.5 mL, H2O 4.8 mL 1.5 M Tris-HCl
pH 7.9, 2.5 mL, 10% SDS, 100 μL, 10% ammonium persulfate, 50 μL,
TEMED, 10 μL) with stacking gel (40% acrylamide/bis, 334 μL, H2O,
2.1 mL, 0.5 M Tris-HCl pH 6.8, 830 μL, 20% SDS 33 μL, 10% ammo-
nium persulfate 13.5 μL, TEMED 6.5 μL) were casted, and the samples
containing 0.5 μg of purified porcine recombinant PREP (purified as
described in Venäläinen et al. [44]) and 1 μM concentration of PREP
inhibitor diluted in native sample buffer (#1610738, Biorad). Samples
were incubated for 30 min in 25 °C and 15 μL were loaded on a native
gel. After electrophoresis, the gel was stained with Coomassie blue
(0.1% Coomassie Blue R250, 45% ethanol and 10% glacial acetic acid)
for 2 h in room temperature and destained (45% methanol, 10% glacial
acetic acid) for 2 × 30 min to get a clear background before it was
scanned.
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2.5. Protein-fragment complementation assay (PCA) for αSyn dimerization
Cell Culture and Transfection. Mouse Neuro-2A (N2A) neuroblastoma
cells and PREP knock out HEK-293 (PREPko) cells were used in the
Protein-Fragment Complementation Assay (PCA). N2A cells were
chosen based on their neuronal background, and HEK-293 PREPko cells
were used based on their better transfectability and availability. N2A
cells were obtained and authenticated by ATCC, and cultured in full
Dulbecco’s modified Eagle’s medium (DMEM) with an additional 10%
(v/v) FBS (Invitrogen), 1% (v/v) L-glutamine-penicillin-streptomycin
solution (Lonza) at 37 °C and 5% CO2. PREPko cells were generated by
CRISPR-Cas9 plasmid targeted to the 3rd exon of the PREP gene as
described in Svarcbahs et al. [42] and were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with an additional 20% (v/v) FBS
(Invitrogen), 1% (v/v) L-glutamine-penicillin-streptomycin solution
(Lonza). Cells were used in passages 4–15. Transfection was done using
JetPei (Polyplus) for N2A cells and Lipofectamine 3000 (#L3000015,
ThermoFisher Scientific) for PREP-KO cells according to the manu-
facturer’s instructions.
Plasmids. The split Gaussia princeps luciferase (GLuc) reporter
plasmids and hPREP expression plasmid used in this study were pre-
viously described in Savolainen et al. [21]. All GLuc constructs used in
this study have the GLuc reporter fragment placed at the N-terminus of
αSyn separated by a (GGGGS)2SG linker.
PCA. PCA was performed as previously described in Savolainen
et al. with small modifications [21]. N2A or PREPko cells were plated
on poly-L-lysine-coated 96-well plates (PerkinElmer Life Sciences,
white wall) at a density of 10,000 cells per well. 24 h post-plating, PCA
reporter plasmids αSyn-GLuc1 (25 ng/well) and αSyn-GLuc2 (25 ng/
well) were transfected together with or without (PREPko cells) non-
tagged human PREP expression plasmid (50 ng/well; Savolainen et al.
[20]).Lactacystin (10 μM, AG Scientific) was used as a positive control.
PCA signal was read at 48 h post-transfection. Cells were treated with
test compounds at 10 μM concentration in phenol red-free DMEM (In-
vitrogen) for 4 h before reading the luminescence. The PCA signal was
detected by injecting 25 μL of native coelenterazine (Nanolight Tech-
nology) per well (final concentration of 20 μM), and the emitted lu-
minescence was read using Varioskan Flash multiplate reader (Thermo
Scientific). For each experimental condition, 4 replicate wells were used
in each experiment, and 3–4 independent experiments with N2A cells
and 2–4 with PREPko cells were performed.
2.6. αSyn in vitro aggregation assay
2.6.1. Proteins
A plasmid containing the human PREP cDNA in the pOT7_hPREP
vector (IMAGE: 3614248) was obtained from GE Dharmacon (Diegem,
Belgium). The coding sequence was PCR cloned in pET-46 Ek/LIC
(Novagene, Madison, WI, USA) with an N-terminal hexahistidine tag
using standard techniques. Human PREP was expressed in BL21(DE3)
cells and purified using immobilized Co-chelating chromatography (GE
Healthcare, Diegem, Belgium) followed by anion exchange chromato-
graphy on a 1 mL Mono-Q column (GE Healthcare). αSyn was expressed
and purified as described by Gerard et al. 2006 [45].
2.6.2. Measurements
Sample consisted of 98 μM αSyn, 25 nM PREP, 1 μM PREP inhibitor,
and 50 μM Thioflavin T in 100 μL buffer (20 mM HEPES, pH 7.40, 150
mM NaCl, 1 mM DTT) containing 0.1% (v/v) DMSO. The amounts of
αSyn and PREP were based on characterization done in Brandt et al.
2008 [15] that showed that even lower amounts of PREP induce αSyn
aggregation. PREP inhibitors were pre-incubated with PREP for 15 min
at room temperature. Control samples, not containing PREP inhibitor
and/or PREP, were also included in the experiment. After carefully
covering the microtiterplate with a transparent sealing film to prevent
evaporation, the sample was placed in the microtiterplate reader (Tecan
Infinite M200, Tecan Group Ltd.) at 37 °C and shaken (orbital, ampli-
tude 3.5 mm, 200 rpm, 10 s). Shaking was continued for 999 s followed
by an absorbance reading (350 nm) and fluorescence reading (Ex/Em
446 nm/482 nm, gain 100 and 80, 40 flashes). The turbidity and
fluorescence course were monitored kinetically every 20 min during
200 h. Magellan software was used to process the experimental data.
2.6.3. Data analysis
All experiments were performed with 6 replicates, except for the
experiments containing an inhibitor but no PREP, which were per-
formed with 3 replicates. The average, minimum, and maximum values
of every experiment were used. Due to the higher robustness of the
fluorescence time course compared to absorbance time course during
the experiments, the fluorescence time course (gain 80) was chosen for
further analysis. The fluorescence time course, emerging from the
binding of thioflavin T to β-fibrils, is a measure of αSyn β-fibrils for-
mation.
2.7. Determination of the unbound partition coefficient (Kpuu)
The unbound partition coefficient (Kpuu) was determined with the
method published previously in other cell models [46–50]. This para-
meter describes the ratio of unbound drug inside the cells and in the cell
exterior, providing a tool to evaluate the intracellular drug exposure.
The parameter is also sometimes referred to as intracellular bioavail-
ability (Fic).
The unbound partition coefficient Kpuu was determined with the
equation below:
= ×Kp Kp fuu u, cell
Where Kp is the cellular accumulation ratio at steady-state, and fu, cell is
the intracellular unbound fraction.
The steady-state cellular accumulation ratio (Kp) was determined by
exposing the mouse N2A cells with 0.5 μM of the PREP inhibitor in
HBSS-Hepes (pH 7.4) for 4 h (at 37 °C). The cells were sub-cultured
onto 48 well plates 24 h prior to the drug exposure. After 4 h of com-
pound exposure, the medium was collected, and the intracellular drug
was extracted with 60:40 acetonitrile-H2O solution (ACN-H2O) con-
taining the internal standard (diclofenac), by incubation at room tem-
perature for 15 min. The medium samples were diluted 1:10 before the
analysis, with the 60:40 ACN-H2O solution containing the internal
standard (diclofenac). The protein amounts in representative cell wells
were determined with the BCA protein assay.
The cellular accumulation ratio (Kp) was calculated with the fol-
lowing equation:
=Kp
Cmedium
A
V
cell
cell
In which the Acell is the intracellular drug amount, Vcell is the vo-
lume of the cells (calculated with 6.5 μL/mg protein) [48,51] and
Cmedium is the compound concentration in the medium.
The intracellular unbound compound fraction (fu, cell) was de-
termined with a dialysis method using Rapid Equilibrium Dialysis in-
serts (Thermo Fischer Scientific), and dialyzing the compounds in cell
lysate for 4 h. The compounds were dialyzed as a cassette, at con-
centration of 0.5 μM each. The fu, homogenate was determined with the
equation below:
=f C
C
u, homogenate buffer
homogenate
Where Cbuffer is the concentration of the compound in the buffer
chamber and the Chomogenate is the compound concentration in the
homogenate chamber. Both samples were treated with either blank cell
homogenate or HBSS-Hepes buffer in order to obtain uniform matrix for
the LC–MS/MS analysis. The samples were diluted with 60:40 ACN-H2O
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solution containing the internal standard (diclofenac) for the LC–MS/
MS analysis.
The intracellular unbound fraction (fu,cell) was calculated with the
following equation:
=
× − +( )f Du, cell
1
1 1f
1
u, homogenate
Where fu, homogenate is the unbound fraction in the homogenate (as de-
scribed above) and the D is a dilution factor, calculated with the
equation below:
=
⎛
⎝
⎞
⎠
× ⎛
⎝
⎞
⎠
D
Proteinconcentration mg
ml
g
ml
protein
1000
6.5 μ
2.8. Determination of compound concentrations
The compound concentrations in cell lysates were determined with
liquid chromatography (Agilent 1290 with Agilent Poroshell 120 SB-
C18 (2.1 × 50 mm, 2.7 μm) column) and a triple-quadrupole mass
spectrometry (Agilent 6495; Agilent Technologies, Inc.) using electro-
spray ionization. The LC–MS/MS conditions are described in Table 2.
Diclofenac was used as an internal standard in all samples.
2.9. Statistical analysis
Data are expressed as mean values± standard error of the mean
(mean± SEM), and negative control average was set as 100% on each
assay to reduce variability between repeats. Error bars in the figures
represent SEM if not otherwise stated in the figure legend. Differences
between groups were analyzed using 1-way ANOVA with Dunnett´s
multiple comparisons post-tests. For N2A cells, αSyn dimerization PCA
two-tailed unpaired student’s t-test compared to DMSO control was
used due the large number of treatment groups. In all cases, p values
of< 0.05 were considered to be significant. Statistical analysis was
performed using PRISM GraphPad statistical software (version 6.07,
GraphPad Software, Inc., San Diego, CA).
3. Results
3.1. Effect of PREP inhibitors on autophagy and correlation to
conformational changes of PREP on native gel
To investigate how different PREP inhibitors induce autophagy, we
measured cellular levels of LC3B-II, an autophagosome marker, using
WB (Fig. 1A). We have earlier shown that pharmacological inhibition
or genetic ablation of PREP induces autophagic flux [20,42], and
therefore, LC3B-II levels were used as an indicator of increased autop-
hagy. The most robust increase in LC3B-II levels were seen with com-
pounds KYP-2091 (104 % increase to DMSO control, p = 0.002, 1-way
ANOVA with Dunnett´s multiple comparison), KYP-2047 (89 % in-
crease to DMSO control, p = 0.001, 1-way ANOVA with Dunnett´s
multiple comparison) and KYP-2189 (86 % increase to DMSO control, p
= 0.0017, 1-way ANOVA with Dunnett´s multiple comparison)
(Fig. 1A). KYP-2101, KYP-2108 and KYP-2112 did not have an effect on
LC3B-II levels. Other studied compounds had an increasing trend on
LC3B-II levels from 40% to 61% compared to DMSO treated control
cells, but no statistical significance was found (Fig. 1A).
As LC3B-II alone is not sufficient to conclude if autophagic flux has
changed [52] we used GFP-LC3-RFP expressing HEK-293 cells to
monitor autophagic flux [43]. After 24 h 10 μM treatment with PREP
inhibitors, no accumulation of LC3B-II vesicles were observed and most
of the compounds induced a small decrease in GFP signal (Fig. 1B).
KYP-2047 and KYP-2091 that showed the most potent increase in LC3B-
II in WB, caused 11% and 9% decrease, respectively, in fluorescence
signal compared to DMSO control (Fig. 1B). When this is combined with
LC3B-II data, our results indicate increased autophagic flux after 24 h.
Since the IC50 value of a given compound did not predict impact on
autophagic flux, we wanted to test the effect of PREP inhibitors on
PREP conformations in native gel to see if weak and potent hydrolytic
inhibitors can cause different conformational changes. Our results show
that the potent inhibitors with IC50 lower than 100 nM locked PREP
into one conformation but weaker inhibitors with IC50 higher than 100
nM did not show the same effect (Fig. 1C). However, conformational
change did not correlate with the effects on LC3B-II levels in the au-
tophagy assay.
3.2. Effect of PREP inhibitors on αSyn dimerization
To investigate the effect of different PREP inhibitors on dimeriza-
tion of αSyn, a live-cell αSyn dimerization PCA was used (Fig. 2). When
PREP was not overexpressed in N2A cells luminescence signal was only
41% of DMSO control (p< 0.0001, t = 21.75, df = 4, Student’s t-test)
(Fig. 2A), and therefore, PREP overexpression was used with N2A cells
in this assay. Of the studied compounds, six were able to decrease
formation of αSyn dimers in the PCA. The most potent compound in
this assay was KYP-2047 with 25% reduction of luminescence signal (p
= 0.0001, t = 5.45, df = 12, Student’s t-test). Compounds SUAM-
1221, KYP-2087, KYP-2091, KYP-2108 and KYP-2117 decreased αSyn
dimerization 12–17% compared to the control cells. Compounds KYP-
2101, KYP-2153, KYP-2189, ZPP and S17092 were not able to reduce
αSyn dimerization in the PCA. To ensure that the observed effect was
PREP-mediated, we treated PREPko cells for 4 h with 10 μM con-
centration of PREP inhibitors (Fig. 2B). No change in luminescence
signal was observed. Lactacystin (luminescence signal 160% compared
to DMSO control, 1-way ANOVA with Dunnett´s multiple comparisons,
p = 0.0044) and 50 ng/well PREP transfection (blank) was used as a
positive control for αSyn dimerization. However, when PREP was re-
stored with transfection, the αSyn dimerization reducing effect was
seen with KYP-2091 (luminescence signal 72% from DMSO control, 1-
way ANOVA with Dunnett´s multiple comparisons, p = 0.0097) and
KYP-2047 (luminescence signal 89% from DMSO control, not sig-
nificant). Interestingly, KYP-2112 caused a small increasing effect on
αSyn dimerization in this assay (luminescence signal 125% compared
to DMSO control, 1-way ANOVA with Dunnett´s multiple comparisons,
p = 0.028).
3.3. Effect of PREP inhibitors on αSyn aggregation in a cell-free assay
Based on the αSyn dimerization assay results, we investigated how
selected PREP inhibitors with distinct structures and IC50 values, KYP-
2047, KYP-2112 and KYP-2091, modulated αSyn aggregation in a cell-
Table 2
The mass spectrometry conditions for compound quantification.
Compound Parent m/z Capillary voltage (V) Fragmentor voltage (V) Daughter m/z (quantifier) Daughter m/z (qualifier) Ionization mode Linear range
2047 340.2 3500 380 243.8 70.2 ESI+ 0.1−500 nM
2112 518.3 3500 380 292.1 351.1 ESI+ 0.1−500 nM
2091 411.3 3500 380 244.0 70.0 ESI+ 0.1−500 nM
Diclofenac 296 3500 380 214 250 ESI+ n.a.
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free assay. Interestingly, unlike in the PCA, all tested inhibitors reversed
the accelerating effect of PREP on αSyn aggregation (Fig. 3). However,
there was no difference between a weak enzymatic inhibitor (KYP-
2091) and strong inhibitors (KYP-2112 and KYP-2047) of the proteo-
lytic activity in this assay, although the concentration used in this assay
(1 μM) is at the IC50 value of KYP-2091 (1010 nM; Table 1; Fig. 3).
Similar to Brandt et al. [15], PREP accelerated the spontaneous αSyn
aggregation process (β-fibril formation) but at the endpoint, the overall
aggregation was higher without PREP (Fig. 3). As the assay was not
performed using aSyn and PREP inhibitors in absence of PREP, we
cannot fully exclude the direct impact of PREP inhibitors on aSyn fi-
brillization.
3.4. Determination of the unbound partition coefficient (Kpuu)
To explain the differences in αSyn PCA and in vitro aggregation
assays, and why a less potent PREP inhibitor (KYP-2091) outperforms
several potent inhibitors in our assays, we next investigated if there was
a difference in cellular penetration of the compounds. To assess the free
concentration inside the cell, we determined the unbound partition
coefficient (Kpuu) for compounds KYP-2047, KYP-2112 and KYP-2091.
All studied PREP inhibitors showed similar Kpuu values (Fig. 4C) ran-
ging from 0.9 to 1.9.
4. Discussion
Previous studies have shown that PREP inhibition by KYP-2047
decreases αSyn aggregation and induces autophagy [16,21], and this
contributes to decreased αSyn levels and toxicity in cells and in vivo
[20]. However, this is the first study where a structurally diverse set of
PREP inhibitors were characterized against αSyn aggregation and as
autophagy inducers.
The studied compounds are inhibitors of the proteolytic activity of
PREP with IC50 values ranging from 0.2 nM to 1010 nM but our results
showed that their effects on the other functions of PREP, αSyn dimer-
ization and autophagy marker LC3B-II upregulation, did not correlate
with the IC50 values. Interestingly, the weakest inhibitor of the pro-
teolytic activity tested in the current study, KYP-2091 with an IC50-
value of 1010 nM, had a clear effect on autophagy and on αSyn di-
merization in the cellular assays. On the other hand, the potent in-
hibitors for proteolytic activity, KYP-2101 and KYP-2112 with IC50-
values of 1.2 and 0.32 nM, respectively, effected neither αSyn dimer-
ization nor LC3-II levels in the autophagy assay. These findings are in
line with our recent study, where we showed that PREP ligands having
a tetrazole group at the P1 site and IC50-values ranging from 12 to even
200 000 nM had a reducing effect on αSyn dimerization in PCA, while
more potent PREP inhibitors did not show the same effect [34]. Im-
portantly, the results with αSyn dimerization and the autophagy assays
suggest that different inhibitors may bind differently on PREP, causing
variable changes to PREP structures that regulate protein-protein in-
teractions. To support this hypothesis, our previous molecular docking
studies suggested that PREP ligands with a tetrazole group bind dif-
ferently to the active site of the enzyme [34].
As KYP-2047 is the only compound of tested inhibitors that has been
Fig. 1. The effect of PREP inhibitors on autophagy. (A) The
effect of tested PREP inhibitors on LC3B-II levels in HEK-293
cells at 1 μM concentration and with 4 h treatment. KYP-2047,
KYP-2091 and KYP-2189 had statistically significant increases
in the levels of LC3B-II: 189%, 204%, and 186 %, respectively,
compared to DMSO control. Data is presented as mean + SEM
(n = 3-7), 1-way ANOVA with Dunnett´s multiple comparison
to DMSO control, ** p<0.05, *** p<0.001. Full images of
blots are shown in Supplementary Fig. S1. (B) The effect of 24
h 10 μM treatment of studied PREP inhibitors on autophagic
flux in GFP-LC3-RFP expressing HEK-293 cells. None of the
tested PREP inhibitors showed accumulation of LC3-II protein
whereas 20 nM bafilomycin 1A (BAF) increased accumulation
of LC3B and inhibited autophagic flux. 500 nM rapamycin
(RAPA) treatment and serum starvation (STARV) induced
autophagic flux significantly even after 24 h treatment. Data
are presented as mean + SEM (n = 3-12), 1-way ANOVA with
Dunnett´s multiple comparison to DMSO control, **
p<0.005, *** p<0.001, **** p<0.0001. Hatched red line
indicates the level of DMSO control. (C) Native gel con-
formation of recombinant human PREP protein in the pre-
sence of selected PREP inhibitors. Potent inhibitors KYP-2047,
KYP-2108 and ZPP changed the equilibrium of PREP con-
formations, but weaker inhibitors KYP-2087 and KYP-2091
did not show such a change. Black arrowhead represents
dominant conformation of PREP, black stars represent minor
conformations of PREP, and the red star represents an un-
specific band seen in all treatments.
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under off-target analysis [53], we cannot fully exclude off-target effects
of give inhibitors. However, our results with the αSyn dimerization
assay in PREPko cells showed that the impact of PREP inhibitors on
αSyn dimerization are PREP-related. Additionally, our earlier results
with PREP knock-out cells show that removal of PREP indeed induces
autophagic flux, and our recent study showed that this is related to
interaction based regulation of PREP on PP2A [20,22]. Differences in
cellular penetration of the compounds could possibly explain the re-
sults. To study this, we selected KYP-2047, KYP-2091, and KYP-2112
for Kpuu assay to determine the unbound partition coefficient, and our
results showed that these results could not be explained by differences
in intracellular drug exposure. The unbound partition coefficient (Kpuu)
is a relevant parameter to evaluate intracellular drug exposure, as it
describes the ratio of free drug inside the cells and in the cell exterior
[47–50]. As lower cellular accumulation was coupled with higher fu,cell
and vice versa the parameter describing the free drug exposure (Kpuu) is
similar among all of the studied PREP inhibitors. This indicates that in
the case of these PREP inhibitors, similar free drug amount is available
Fig. 2. The effect of PREP inhibitors on αSyn dimerization.
(A) αSyn dimerization in N2A cells as determined by protein-
fragment complementation assay (PCA) with PREP over-
expression (PREP inhibitors added at 10 μM final concentra-
tion for 4 h). Compounds SUAM-1221, KYP-2047, KYP-2087,
KYP-2091, KYP-2108 and KYP-2117 reduced the amount of
αSyn1-αSyn2 interaction 12-25% of control. KYP-2047
showed the most potent effect on αSyn dimerization with 25%
reduction, while KYP-2091 being the least potent with 12%
reduction in αSyn dimerization. αSyn1+αSyn2+mock cells
served as a negative control for αSyn dimerization as there is
no PREP overexpression. Data are presented as mean + SEM,
(n = 3-11), (*** p<0.001, **p<0.01, *p<0.05; Student´s
t-test compared to DMSO control). (B) αSyn dimerization in
PREPko cells. No effect with PREP inhibitors were observed
when PREP was not present in the cells. Transfection of hPREP
increased αSyn dimerization and PREP inhibitor KYP-2047
(not statistically significant) and KYP-2091 were able to de-
crease this compared to DMSO control. Data are presented as
mean + SEM, 1-way ANOVA with Dunnett´s multiple com-
parison to DMSO control, *p<0.05, ** p<0.005. Hatched
red line indicates the level of DMSO control.
Fig. 3. Impact of PREP inhibitors αSyn aggregation in vitro. αSyn aggregation assay (β-sheet formation followed by Thioflavin-T) was performed in the presence
or absence of PREP and PREP inhibitors in a cell-free assay.
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inside the cells to bind to the target, when the exposure concentration is
equal. The determined Kpuu values were in the range of 0.9–1.9, in-
dicating that passive permeation across the plasma membrane dom-
inates the equilibrium, and active processes (active transport, metabo-
lism) or intracellular sequestration (e.g. lysosomotropism) are not
significantly altering the cellular kinetics of these compounds.
The in vitro αSyn aggregation assay showed that all studied com-
pounds: KYP-2047, KYP-2091, and KYP-2112 prevented the formation
of αSyn fibrils similar to Brandt et al. 2008 [15]. This is slightly con-
troversial compared to the αSyn PCA results but notably, compound
KYP-2091, with an IC50 value that is over 1000-fold higher compared to
IC50 values of other tested compounds, had the best impact on reversing
the αSyn aggregation in the cell-free assay. The concentration of PREP
inhibitors used in the measurements were 1000 nM which means that
with KYP-2091 approximately 50% of the PREP still had proteolytic
activity. This indicates that the magnitude of inhibition of PREP’s
proteolytic activity does not correlate directly with the reduction of
αSyn aggregation in the cell-free assay. Interestingly, compound KYP-
2112 was not able to decrease αSyn dimerization in the αSyn PCA, but
decreased the aggregation in vitro. This might be due to a significantly
more complex environment in the cell-based model.
As stated above, we suggest that different biological activity profiles
by different PREP inhibitors is most likely resulting from differences in
how the bound PREP ligands stabilize or allow certain flexibility of the
conformation of the enzyme, especially the loops around the active site.
The hypothesis is that the required conformation of the enzyme is not
equivalent for an effect of PREP on autophagy, αSyn aggregation, and
proteolytic activity. Our view is supported by our previous study, where
we showed that a mutation in external loop B at the surface of PREP
(T590C) removed the inhibitory activity of PREP on PP2A [22]. The
native gel assay showed that conformational changes of PREP is in line
with the IC50-value of tested compounds as small molecules having an
IC50 lower than 10 nM changed the equilibrium of conformations.
However, the changes seen in the native gel did not follow the autop-
hagy induction or αSyn dimerization reducing effect. Changes in native
gel conformations are likely to be more drastic compared to the subtle
movements of PREP loops which might modulate protein-protein in-
teractions [24]. This is supported by the multiple quantum relaxation
dispersion assay where ZPP and KYP-2047 gave slightly different
spectra on PREP even though they are both potent inhibitors and have
the same effect on the native gel [54]. There are also other reports
where potent inhibitors of PREP proteolytic activity have different
biological effects. For example, KYP-2047 and SUAM-14746 had a
different impact on trophoblast stem cell differentiation [55] and that
weak PREP inhibitors are able to decrease the amount of mutant αSyn
in neuroblastoma cells [56]. Therefore, the effect of different PREP li-
gands on the PREP conformation requires detailed protein structure
studies.
Our study shows that ligands with a close structural similarity to
SUAM-1221 (the inhibitor having only the 4-phenylbutanoyl-L-prolyl-
pyrrolidine backbone) are preferred for the αSyn dimerization reducing
effect. However, introduction of an electrophile at the P1 site seems to
change the situation slightly. For example, ZPP, with a formyl group at
the P1 site, was not able to decrease αSyn dimerization whereas KYP-
2108 with a hydroxyacetyl group in the same position had an effect on
αSyn dimerization. A more reactive electrophilic group is likely to
anchor it strongly to the active site of the enzyme and thereby de-
creasing the opportunity for alternative binding modes, which may
affect the conformational flexibility of PREP. The nitrile in KYP-2047,
hydroxyacetyl in KYP-2108, and ketone in KYP-2091 are less reactive
electrophiles than an aldehyde in ZPP indicating that a too strong
electrophile might not be preferable. This is supported by the fact that
compounds SUAM-1221 and KYP-2087 lacking the electrophile has a
reducing effect on αSyn dimerization in the PCA. On the other hand,
adding an electrophile in some scaffolds might lead to a decreasing
effect on αSyn dimerization in PCA as seen when comparing com-
pounds KYP-2101 and KYP-2117.
In conclusion, PREP ligands are likely to regulate the effect of PREP
on autophagy and αSyn aggregation through a conformational stabili-
zation of the enzyme that is not equivalent to inhibiting its proteolytic
activity. From the perspective of drug discovery, it would be beneficial
to develop PREP ligands with an increased selectivity towards the au-
tophagy inducing effect and/or αSyn dimerization reducing effect.
However, the exact mechanisms by which small molecular compounds
regulate these protein-protein interaction mediated functions of PREP
need to be studied further for better understanding of the decoupled
structure-activity relationships that we have revealed in this study.
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